The top 20 #MajorPROsASH list is complete! A truly phenomenal year at #ASH22 with a (growing!) plethora of PRO abstracts from which to choose. Please send along any others you found, and safe travels back home. #MajorPROs cc @ASH_hematology@twitter.com

RT @majorajay@twitter.com

Here we go! Announcing this year's top 20 patient-reported outcomes abstracts at #ASH22. Follow along in this thread for the latest thought-provoking (and provocative!) #qualityoflife studies in hematology. 🧵#MajorPROs #MajorPROsASH #ASH2022 cc @ASH_hematology@twitter.com

Next bolus of @ASH_hematology@twitter.com #ASH22 patient-reported outcomes abstracts in this thread! #MajorPROs #MajorPROsASH

Distress on NCCN Distress Thermometer = inferior overall survival in AML. What drives this and amenable to intervention? #leusm

I am straight up fangirling in this #ASH22 #lymsm session. As a PRO researcher, I have discussed this 2014 study by Ardeshna et al. hundreds of times, as a high-quality follicular lymphoma trial in which quality of life was a co-primary endpoint. We need more of this. #MajorPROs

Given EORTC QLQ-C30 MID of 6 when comparing means in #mmsm, improvements in pain and fatigue also appear meaningfully better with DRVd over time. Preserved global health & less severe tx-related side effects as well. #ASH22 #MajorPROs

RT @majorajay@twitter.com

Will do a deep dive once the manuscript is published, but the GRIFFIN QOL data looks quite good on favor of dara-VRd for multiple symptom domains. #mmsm #ASH22

Re: MAIA PRO data #ASH22: the minimally important difference in #mmsm when comparing mean changes for the EORTC QLQ-30 is 6. So, looks like pain improvement with dara-Rd is clinically meaningful, not with other domains. #MajorPROs

1/

RT @majorajay@twitter.com

Here we go! Announcing this year's top 20 patient-reported outcomes abstracts at #ASH22. Follow along in this thread for the latest thought-provoking (and provocative!) #qualityoflife studies in hematology. 🧵#MajorPROs #MajorPROsASH #ASH2022 cc @ASH_hematology@twitter.com

🐦🔗: https://twitter.com/majorajay/status/1601015620128342016

Just stopped by the #ASH22 poster hall and there are a HUGE number of PRO abstracts, way more than #ASH21. 🫶🏼👏🏾🎉

Going to tweet out a few fantastic patient-reported outcomes posters in this thread. 🧵 #MajorPROs #MajorPROsASH

Okay, but what PRO instrument are you using? SHAVE-PRO? EQ-RZR-D? Does it have content validity? What about established MCIDs? Sounds like it's time for another #MajorPROs thread! #ASH22 🧔🏽🧔🏻🧔🏼

RT @Jacawalk@twitter.com

If you spot my husband @majorajay@twitter.com at #ASH22 please compliment him on his clean shave because he took my razor to New Orleans, negatively impacting my quality of life. This patient is reporting negative outcomes (too much stubble) 🧔🏼‍♂️ https://twitter.com/majorajay/status/1601015620128342016

Good morning, @ASH_hematology@twitter.com #ASH22! Added a few more early-morning PRO abstracts to the below thread over coffee. 👇🏽👇🏽 See you all soon! #MajorPROsASH

RT @majorajay@twitter.com

Here we go! Announcing this year's top 20 patient-reported outcomes abstracts at #ASH22. Follow along in this thread for the latest thought-provoking (and provocative!) #qualityoflife studies in hematology. 🧵#MajorPROs #MajorPROsASH #ASH2022 cc @ASH_hematology@twitter.com

Here we go! Announcing this year's top 20 patient-reported outcomes abstracts at #ASH22. Follow along on my Twitter thread for the latest thought-provoking (and provocative!) #qualityoflife studies in hematology. 🧵#MajorPROs #MajorPROsASH #ASH2022

https://twitter.com/majorajay/status/1601015620128342016?t=h4Pw0R9NyNAd4zkBt9hErQ&s=19

Here we go! Announcing this year's top 20 patient-reported outcomes abstracts at #ASH22. Follow along in this thread for the latest thought-provoking (and provocative!) #qualityoflife studies in hematology. 🧵#MajorPROs #MajorPROsASH #ASH2022 cc @ASH_hematology@twitter.com

Happy #ASH22 week! After reviewing all the patient-reported outcomes abstracts @ash_hematology@twitter.com this year, I'll be highlighting my top 20 #MajorPROs abstracts starting tomorrow, with new additions I find down in #NOLA. Stay tuned! #MajorPROsASH

Very proud of this #ASH22 abstract which elucidates why just reporting global QOL as a patient-reported outcome is insufficient in capturing dynamic changes in symptom burden in the trial setting. #mmsm #MajorPROs #MajorPROsASH

https://ashpublications.org/blood/article/140/Supplement%201/12593/489446/Global-Health-Status-Inadequately-Captures